| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.bplindia.in | |
| Market Cap | 199.31 Cr. | |
| Enterprise Value(EV) | 235.57 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 28.52 | Trailing Twelve Months Ending 2022-09 |
| Price-Earning Ratio (PE) | 12.10 | Trailing Twelve Months Ending 2022-09 |
| Industry PE | 32.22 | Trailing Twelve Months Ending 2022-09 |
| Book Value / Share | 306.52 | Trailing Twelve Months Ending 2022-09 |
| Price to Book Value | 1.13 | Calculated using Price: 345.05 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 0.58 Cr. | 5,774,666 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| The company is engaged in to the business of the Pharmaceuticals & Drugs. | ||
| 1 Day |
|
-5.25% |
| 1 Week |
|
+7.78% |
| 1 Month |
|
+5.84% |
| 3 Month |
|
-0.56% |
| 6 Month |
|
+1.49% |
| 1 Year |
|
-22.52% |
| 2 Year |
|
-7.24% |
| 5 Year |
|
|
| 10 Year |
|
| 7 years | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 11.38 | 11.45 | 13.35 | 25.47 | 22.76 | 15.53 | 13.46 | |
| Return on Capital Employed (%) | 14.23 | 11.47 | 18.10 | 39.30 | 30.83 | 20.24 | 17.18 | |
| Return on Assets (%) | 5.37 | 5.99 | 7.61 | 14.71 | 13.94 | 10.52 | 9.80 |
| Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 57 | 64 | 73 | 94 | 118 | 144 | 166 | 177 | |
| Non Curr. Liab. | 7 | 3 | 0 | 4 | 3 | 11 | 14 | 12 | |
| Curr. Liab. | 56 | 43 | 57 | 61 | 66 | 44 | 42 | 95 | |
| Minority Int. | 0 | 4 | 22 | ||||||
| Equity & Liab. | 120 | 110 | 130 | 159 | 188 | 199 | 226 | 306 | |
| Non Curr. Assets | 49 | 46 | 39 | 41 | 56 | 51 | 82 | 119 | |
| Curr. Assets | 72 | 64 | 91 | 118 | 132 | 148 | 144 | 186 | |
| Misc. Exp. not W/O | |||||||||
| Total Assets | 120 | 110 | 130 | 159 | 188 | 199 | 226 | 306 |
| Particulars | 8 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
| Net Sales | 124 | 111 | 137 | 220 | 228 | 205 | 212 | 199 | |
| Other Income | 5 | 8 | 7 | 13 | 12 | 9 | 8 | 11 | |
| Total Income | 129 | 119 | 144 | 232 | 240 | 213 | 220 | 210 | |
| Total Expenditure | -114 | -105 | -124 | -191 | -201 | -179 | -184 | -181 | |
| PBIDT | 15 | 14 | 19 | 42 | 40 | 34 | 36 | 29 | |
| Interest | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Depreciation | -4 | -6 | -6 | -6 | -6 | -6 | -7 | -6 | |
| Taxation | -3 | -1 | -4 | -13 | -9 | -7 | -7 | -6 | |
| Exceptional Items | |||||||||
| PAT | 6 | 7 | 9 | 21 | 24 | 20 | 21 | 16 | |
| Minority Interest | 0 | 0 | 0 | ||||||
| Share Associate | |||||||||
| Other Related Items | |||||||||
| Consolidated Net Profit | 6 | 7 | 9 | 21 | 24 | 20 | 21 | 16 | |
| Adjusted EPS | 11 | 12 | 16 | 37 | 42 | 36 | 36 | 29 |
| Particulars | 7 years | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | -2 | 6 | 20 | 14 | 24 | -1 | ||
| Cash Fr. Inv. | -2 | -8 | -9 | -13 | -43 | -7 | ||
| Cash Fr. Finan. | -8 | 4 | -4 | -3 | 11 | 9 | ||
| Net Change | -11 | 2 | 7 | -1 | -8 | 2 | ||
| Cash & Cash Eqvt | 2 | 4 | 11 | 10 | 2 | 3 |
|
Fri, 13 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Confirmation Certificate pursuant to provisions of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations 2018 duly sent and confirmed by Adroit Corporate Services Private Limited viz. Companys Registrar and Share Transfer Agent registered with Securities and Exchange Board of India for the period ended on 31st December 2022. |
|
Sat, 31 Dec 2022
Closure of Trading Window Pursuant to Companys Code of Conduct framed in accordance with the SEBI (Prohibition of Insider Trading) Regulations 2015 as amended the Trading Window for dealing in the securities of the company for all designated persons specified under the Code shall remain close form 02nd January 2023 onwards till 48 hours after the declaration of Unaudited Financial Results for the quarter ended 31st December 2022 (both days inclusive). |
|
Sat, 12 Nov 2022
Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Unaudited Financial Results For The Quarter And Half Year Ended 30Th September 2022. In compliance of Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Board of Directors of the Company in its meeting held on 12th November 2022 has considered and approved the Unaudited Financial Results for the Quarter and half year ended 30th September 2022 and taken on record Limited Review Report issued by the Statutory Auditors of the Company.In this respect we hereby enclose following:1. Unaudited Financial Results for the Quarter and Half year ended 30th September 2022.2. Limited Review Report on the said Financial Results. |
| Fri, 03 Feb 2023 |
High Delivery Percentage
|
Close Crossing Last Month Close from Above
|
Closing Below Previous Low
|
Close Above Last Week High
|
High Increase in 1 Month
|
Equities
M.F.
Sectors